Metabasis Inks Agreement With Merck

San Diego-based Metabasis announced this morning that it is expanding its collaboration with Merck on a treatment for hepatitis C. The two companies are working together to develop a small molecule therapeutic for treatment of hepatitis C virus infections. Merck will continue to fund and collaborate on drug candidates based on Metabasis drug technology. Metabasis is public and was funded by Interwest Partners, ITOCHU, Maverick Capital, MPM Capital, Pan Pacific, Sprout Group, and Wellcome Trust.